Efavirenz

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Efavirenz is an ofp drug in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1998. Its mechanism of action is classified as Cytochrome P450 2B6 Inducers, Cytochrome P450 2C19 Inhibitors and Cytochrome P450 2C9 Inhibitors. DrugCentral lists 9 molecular targets, including reverse transcriptas, pol and env. Recorded indications include Human immunodeficiency virus infection.

• Approval status: ofp (first approved 1998 by the FDA).
• Drug class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor.
• Mechanism of action: Cytochrome P450 2B6 Inducers; Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C9 Inhibitors.
• Molecular targets: reverse transcriptas, pol, env and gag-pol (9 listed in DrugCentral).
• Indications: Human immunodeficiency virus infection.
• ATC code: J05AG03 (Non-nucleoside reverse transcriptase inhibitors).
• Molecular formula: C14H9ClF3NO2; molecular weight 315.68 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Human immunodeficiency virus infection

Off-label uses (1)

• Prevention of HIV Infection after Exposure

Contraindications (30)

• Acute nephropathy
• Aggressive behavior
• Breastfeeding (mother)
• Cardiovascular disease
• Chronic hepatitis C
• Chronic type B viral hepatitis
• Depressive disorder
• Disease of liver
• Family history of sudden death
• Fanconi syndrome
• Hepatic failure
• Hypercholesterolemia
• Hypertriglyceridemia
• Hypokalemia
• Hypomagnesemia
• Hypophosphatemia
• Kidney disease
• Lactic acidosis
• Liver function tests abnormal
• Mania
• Obesity
• Osteomalacia
• Osteopenia
• Paranoid disorder
• Pathological fracture
• Pregnancy, function
• Prolonged QT interval
• Seizure disorder
• Steatosis of liver
• Suicidal thoughts

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 2B6 Inducers; Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 3A Inducers; Cytochrome P450 3A4 Inhibitors; Non-Nucleoside Reverse Transcriptase Inhibitors
• Established pharmacologic class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Molecular targets (9)

Target	Gene	Action	Activity
Reverse transcriptase	reverse transcriptas	unknown	IC50 8.89
Reverse transcriptase/RNaseH	pol	inhibitor	Ki 8.52
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120	env	unknown	IC50 8.46
Gag-Pol polyprotein	gag-pol	inhibitor	IC50 8.30
Reverse transcriptase protein	reverse transcriptase	unknown	Ki 8.07
Cholesterol 24-hydroxylase	CYP46A1	unknown	Kd 6.10
Cytochrome P450 3A4	CYP3A4	inhibitor	IC50 4.76
ATP-binding cassette sub-family G member 2	ABCG2	unknown	IC50 4.69
Nuclear receptor subfamily 1 group I member 2	NR1I2	unknown	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
1999-05-28	EMA	—	Bristol-Myers Squibb Pharma EEIG
1998-09-17	FDA	—	BRISTOL MYERS SQUIBB

ATC classification

ATC code	Therapeutic hierarchy
J05AG03	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Non-nucleoside reverse transcriptase inhibitors
J05AR06	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
J05AR11	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: CYP2B6 · Informative PGx
• FDA label: CYP2B6 · Informative PGx
• HCSC label: CYP2B6 · Informative PGx
• PMDA label: CYP2B6 · Actionable PGx
• Swissmedic label: CYP2B6 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Virologic failure	4487.8
Viral mutation identified	3054.6
Pathogen resistance	2203.5
Immune reconstitution inflammatory syndrome	1902.2
Drug resistance	1876.7
Drug interaction	1535.2
Depression	1128.8
Foetal exposure during pregnancy	1081.2
Lipodystrophy acquired	947.4
Psychiatric decompensation	619.6
Depression suicidal	538.7
Abortion spontaneous	496.3

Chemical structure

• Molecular formula: C₁₄H₉ClF₃NO₂
• Molecular weight: 315.68 g/mol
• CAS number: 154598-52-4
• InChIKey: XPOQHMRABVBWPR-ZDUSSCGKSA-N
• PubChem CID: 64139

FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Efavirenz used for?

DrugCentral lists the following indications for Efavirenz: Human immunodeficiency virus infection.

How does Efavirenz work?

Efavirenz is classified as Cytochrome P450 2B6 Inducers, Cytochrome P450 2C19 Inhibitors and Cytochrome P450 2C9 Inhibitors; its molecular targets in DrugCentral include reverse transcriptas, pol (inhibitor), env and gag-pol (inhibitor).

When was Efavirenz first approved?

Efavirenz was first approved by the FDA in 1998.

What drug class does Efavirenz belong to?

Efavirenz is in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class.

What is the chemical formula of Efavirenz?

Efavirenz has the molecular formula C14H9ClF3NO2 and a molecular weight of 315.68 g/mol.

Sources

• DrugCentral drug card 989 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL223228 — compound record and bioactivity
• PubChem CID 64139 — chemical identifiers
• DrugBank DB00625 — drug record
• FDA UNII JE6H2O27P8 — substance identity
• DailyMed: FDA labels for Efavirenz — current prescribing information (label search)
• UniProt Q9Y6A2 (CYP46A1) — target protein
• UniProt P08684 (CYP3A4) — target protein
• UniProt Q9UNQ0 (ABCG2) — target protein
• UniProt O75469 (NR1I2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.